کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11019515 | 1718102 | 2018 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DLBCLIFRTWaldeyer’s ringCRUNHLPET-CTIPIECoGDFSPFs - PF هاImmunochemotherapy - ایمونوخموتراپیDisease free survival - بقای آزاد بیماریProgression free survival - بقای آزاد شدن پیشرفتoverall survival - بقای کلpositron emission tomography-computed tomography - توموگرافی کامپیوتری انتشارات پوزیترونRadiotherapy - رادیوتراپیcomplete remission - رمی کاملWorld Health Organization - سازمان بهداشت جهانیInternational Prognostic Index - شاخص پیشگویی بین المللیeastern cooperative oncology group - شرق گروه تعاونی انکولوژیconfidence interval - فاصله اطمینانlactate dehydrogenase - لاکتات دهیدروژناز LDH - لاکتات دهیدروژناز به صورت مختصر شده LDH Diffuse large B-cell lymphoma - لنفوم سلول B بزرگ سلول بزرگNon-Hodgkin’s lymphoma - لنفوم غیر هودقینhazard ratio - نسبت خطرPerformance status - وضعیت عملکردWHO - که
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy](/preview/png/11019515.png)
چکیده انگلیسی
The standard treatment of waldeyer's ring DLBCL remains controversial. This retrospective study was designed to evaluate the role of consolidation radiotherapy (RT) in patients with stage I/II diffuse large B-cell lymphoma (DLBCL) limited in Waldeyer's ring (WR). We included 72 patients, 42 were treated with immunochemotherapy alone (CT group) and 30 were treated with immunochemotherapy followed by radiotherapy (CTâ+âRT group). All patients received at least 3 cycles of R-CHOP regimen and achieved complete remission (CR) after immunochemotherapy. After 53 months median follow-up time, the 5-year progression-free survival (PFS) rates in CTâ+âRT group vs. CT group were 93.3% vs. 92.5% (Pâ=â0.896), the 5-year overall survival (OS) rates were 96.7% vs. 94.4% (Pâ=â0.649). Patients with oropharyngeal primary had relatively better 5-year PFS and OS rates compared to nasopharyngeal primary (PFS: 98.2% vs. 73.3%, pâ=â0.001; OS: 100% vs. 79.0%, pâ<â0.001). Moreover, the primary site was the only independent prognostic factor for PFS in the multivariate analysis (pâ=â0.012, HR 16.858 [95% CI: 1.883-150.933]).
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 74, November 2018, Pages 80-85
Journal: Leukemia Research - Volume 74, November 2018, Pages 80-85
نویسندگان
Chunyan Li, Xuejun Ma, Ziqiang Pan, Fangfang Lv, Zuguang Xia, Kai Xue, Qunling Zhang, Dongmei Ji, Junning Cao, Xiaonan Hong, Ye Guo,